New hope for tough lung cancer: drug combo targets liver spread
NCT ID NCT05588388
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the drug bevacizumab to standard chemo-immunotherapy can help people with extensive-stage small cell lung cancer that has spread to the liver. About 39 participants will receive the combination for up to a year. The goal is to see if it delays cancer growth and is safe to use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute
RECRUITINGLos Angeles, California, 90048, United States
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
-
V.A. Ann Arbor Healthcare System
RECRUITINGAnn Arbor, Michigan, 48105, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new test could reveal how radiation affects the liver
- A new clue in the fight against colorectal cancer recurrence?
- A new way to read CT scans may predict which liver surgery patients will develop Life-Threatening failure
- Can a Two-Drug attack shrink tough lung cancers?
- Could a two-vein embolization trick turn inoperable liver tumors into operable ones?
- Targeted chemotherapy pump takes fight directly to pancreatic cancer liver tumors